158 related articles for article (PubMed ID: 28012969)
21. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
[TBL] [Abstract][Full Text] [Related]
22. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
23. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
24. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
[TBL] [Abstract][Full Text] [Related]
26. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism.
Budczies J; Brockmöller SF; Müller BM; Barupal DK; Richter-Ehrenstein C; Kleine-Tebbe A; Griffin JL; Orešič M; Dietel M; Denkert C; Fiehn O
J Proteomics; 2013 Dec; 94():279-88. PubMed ID: 24125731
[TBL] [Abstract][Full Text] [Related]
27. Dual Roles of 17-β Estradiol in Estrogen Receptor-dependent Growth Inhibition in Renal Cell Carcinoma.
Chen KC; Lin CM; Huang CJ; Chen SK; Wu ST; Chiang HS; Ku WC
Cancer Genomics Proteomics; 2016; 13(3):219-30. PubMed ID: 27107064
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells.
Ren J; Li W; Liu H; Yan L; Jiao W; Li D; Tang Y; Gu G; Xu Z
Urol Oncol; 2013 Oct; 31(7):1358-66. PubMed ID: 22341977
[TBL] [Abstract][Full Text] [Related]
29. GC-TOF/MS-based metabolomics approach to study the cellular immunotoxicity of deoxynivalenol on murine macrophage ANA-1 cells.
Ji J; Sun J; Pi F; Zhang S; Sun C; Wang X; Zhang Y; Sun X
Chem Biol Interact; 2016 Aug; 256():94-101. PubMed ID: 27350164
[TBL] [Abstract][Full Text] [Related]
30. High expression of fructose-bisphosphate aldolase A induces progression of renal cell carcinoma.
Huang Z; Hua Y; Tian Y; Qin C; Qian J; Bao M; Liu Y; Wang S; Cao Q; Ju X; Wang Z; Gu M
Oncol Rep; 2018 Jun; 39(6):2996-3006. PubMed ID: 29693182
[TBL] [Abstract][Full Text] [Related]
31. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
32. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma.
Zhang Y; Yuan Y; Liang P; Guo X; Ying Y; Shu XS; Gao M; Cheng Y
Oncotarget; 2017 May; 8(18):30008-30018. PubMed ID: 28404905
[TBL] [Abstract][Full Text] [Related]
33. SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma.
Zhao W; Zhou J; Deng Z; Gao Y; Cheng Y
Int J Oncol; 2016 Sep; 49(3):1001-8. PubMed ID: 27572476
[TBL] [Abstract][Full Text] [Related]
34. Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.
Abbott KL; Ali A; Reinfeld BI; Deik A; Subudhi S; Landis MD; Hongo RA; Young KL; Kunchok T; Nabel CS; Crowder KD; Kent JR; Madariaga MLL; Jain RK; Beckermann KE; Lewis CA; Clish CB; Muir A; Rathmell WK; Rathmell J; Vander Heiden MG
Elife; 2024 May; 13():. PubMed ID: 38787918
[TBL] [Abstract][Full Text] [Related]
35. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.
Beyoğlu D; Imbeaud S; Maurhofer O; Bioulac-Sage P; Zucman-Rossi J; Dufour JF; Idle JR
Hepatology; 2013 Jul; 58(1):229-38. PubMed ID: 23463346
[TBL] [Abstract][Full Text] [Related]
36. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.
Copland JA; Luxon BA; Ajani L; Maity T; Campagnaro E; Guo H; LeGrand SN; Tamboli P; Wood CG
Oncogene; 2003 Sep; 22(39):8053-62. PubMed ID: 12970754
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile.
Cifola I; Spinelli R; Beltrame L; Peano C; Fasoli E; Ferrero S; Bosari S; Signorini S; Rocco F; Perego R; Proserpio V; Raimondo F; Mocarelli P; Battaglia C
Mol Cancer; 2008 Jan; 7():6. PubMed ID: 18194544
[TBL] [Abstract][Full Text] [Related]
38. Gene signatures of progression and metastasis in renal cell cancer.
Jones J; Otu H; Spentzos D; Kolia S; Inan M; Beecken WD; Fellbaum C; Gu X; Joseph M; Pantuck AJ; Jonas D; Libermann TA
Clin Cancer Res; 2005 Aug; 11(16):5730-9. PubMed ID: 16115910
[TBL] [Abstract][Full Text] [Related]
39. Metabolic alterations in renal cell carcinoma.
Massari F; Ciccarese C; Santoni M; Brunelli M; Piva F; Modena A; Bimbatti D; Fantinel E; Santini D; Cheng L; Cascinu S; Montironi R; Tortora G
Cancer Treat Rev; 2015 Nov; 41(9):767-76. PubMed ID: 26169313
[TBL] [Abstract][Full Text] [Related]
40. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
